Reason for request
Inclusion
Clinical Benefit
| Substantial |
The actual benefit is substantial in the indication in the Marketing Authorisation. |
Clinical Added Value
| no clinical added value |
DEXDOR does not offer any improvement in actual benefit (non-existent IAB) in comparison with propofol and midazolam in the light to moderate sedation of adults in intensive care units. |
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
fpepfnkdHthGC6Aw
